{"protocolSection": {"identificationModule": {"nctId": "NCT02237508", "orgStudyIdInfo": {"id": "Z7200J02"}, "secondaryIdInfos": [{"id": "2014-002081-69", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Zambon SpA", "class": "INDUSTRY"}, "briefTitle": "A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers", "officialTitle": "An Open-Label, Single-dose, Randomized, Five-Period Cross-over to Compare Pharmacokinetics Profiles of Z7200 and Symbicort Turbohaler, With and Without Charcoal Blockade in Healthy Volunteers."}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-09"}, "primaryCompletionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-09-02", "studyFirstSubmitQcDate": "2014-09-08", "studyFirstPostDateStruct": {"date": "2014-09-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-10-06", "resultsFirstSubmitQcDate": "2021-11-15", "resultsFirstPostDateStruct": {"date": "2022-01-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-02-09", "lastUpdatePostDateStruct": {"date": "2022-02-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Zambon SpA", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective was:\n\n- to assess the bioequivalence of a single dose (two inhalations) of the test product compared to the reference product, with and without charcoal blockade.\n\nThe secondary objectives were:\n\n* to assess the pharmacokinetic profile of budesonide and formoterol in plasma after a single dose (two inhalations) of the test product and the reference product, with and without charcoal blockade.\n* to assess the safety and tolerability of the test product and the reference product, with and without charcoal blockade.", "detailedDescription": "This was a single center, open label, randomized, five-period crossover, single-dose study in healthy volunteers aged 18 to 45 years. A total of 90 volunteers were enrolled, with 9 subjects in each of the 10 treatment sequences.\n\nThe study consisted of 5 treatment periods, each lasting approximately 48h, separated by a washout period of a minimum of 5 days. RS01 and/or Symbicort Turbohaler device use training was provided on Day -1 and Day 1 of each treatment period. Subjects were screened for eligibility to participate in the study -28 to -2 days prior to the first treatment period, and were randomized to one of 10 treatment sequencies containing the following 5 treatment arms on Day 1 of the first treatment period:\n\nTreatment A: Z7200 without oral activated charcoal\\* Treatment B1: Symbicort 1 without oral activated charcoal\\* Treatment B2: Symbicort 2 without oral activated charcoal\\* Treatment C: Z7200 with oral activated charcoal\\*\\* Treatment D: Symbicort with oral activated charcoal\\*\\*\n\nSubjects were admitted to the clinical unit at 8.00 on the morning of Day -1, and were dosed on the morning of Day 1 following an overnight fast (minimum of 8h). On Day 2, following collection of the 24-h PK blood sample, subjects were discharged.\n\n\\* Subjects who received treatments A, B1 and B2 rinsed their mouth vigorously with 50 mL water for 3 to 5 sec immediately after the second inhalation.\n\n\\*\\* A charcoal blockade was used to prevent absorption from oropharyngeal and GI tract, in order to assess the pulmonary deposition of budesonide and formoterol, with periods performed without a charcoal blockade allowing the assessment of the total systemic exposure to the drug."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 90, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "A-B1-B2-C-D", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 days followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "B1-C-A-D-B2", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "C-D-B1-B2-A", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "D-B2-C-A-B1", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "B2-A-D-B1-C", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "D-C-B2-B1-A", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "B2-D-A-C-B1", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "A-B2-B1-D-C", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "B1-A-C-B2-D", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}, {"label": "C-B1-D-A-B2", "type": "EXPERIMENTAL", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following five treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B2: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period of a minimum of 5 day followed treatment periods 1 to 4.\n\nTreatment B1 and B2 denote Symbicort without oral activated charcoal administered in two different period, designated as Symbicort 1 and Symbicort 2.", "interventionNames": ["Drug: Z7200 without oral activated charcoal", "Drug: Symbicort Turbohaler without oral activated charcoal", "Drug: Z7200 with oral activated charcoal", "Drug: Symbicort Turbohaler with oral activated charcoal"]}], "interventions": [{"type": "DRUG", "name": "Z7200 without oral activated charcoal", "description": "160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).", "armGroupLabels": ["A-B1-B2-C-D", "A-B2-B1-D-C", "B1-A-C-B2-D", "B1-C-A-D-B2", "B2-A-D-B1-C", "B2-D-A-C-B1", "C-B1-D-A-B2", "C-D-B1-B2-A", "D-B2-C-A-B1", "D-C-B2-B1-A"], "otherNames": ["budesonide/formoterol"]}, {"type": "DRUG", "name": "Symbicort Turbohaler without oral activated charcoal", "description": "320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).", "armGroupLabels": ["A-B1-B2-C-D", "A-B2-B1-D-C", "B1-A-C-B2-D", "B1-C-A-D-B2", "B2-A-D-B1-C", "B2-D-A-C-B1", "C-B1-D-A-B2", "C-D-B1-B2-A", "D-B2-C-A-B1", "D-C-B2-B1-A"], "otherNames": ["budesonide/formoterol"]}, {"type": "DRUG", "name": "Z7200 with oral activated charcoal", "description": "160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).", "armGroupLabels": ["A-B1-B2-C-D", "A-B2-B1-D-C", "B1-A-C-B2-D", "B1-C-A-D-B2", "B2-A-D-B1-C", "B2-D-A-C-B1", "C-B1-D-A-B2", "C-D-B1-B2-A", "D-B2-C-A-B1", "D-C-B2-B1-A"], "otherNames": ["budesonide/formoterol with coadministration of charcoal"]}, {"type": "DRUG", "name": "Symbicort Turbohaler with oral activated charcoal", "description": "320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).", "armGroupLabels": ["A-B1-B2-C-D", "A-B2-B1-D-C", "B1-A-C-B2-D", "B1-C-A-D-B2", "B2-A-D-B1-C", "B2-D-A-C-B1", "C-B1-D-A-B2", "C-D-B1-B2-A", "D-B2-C-A-B1", "D-C-B2-B1-A"], "otherNames": ["budesonide/formoterol with coadministration of charcoal"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "AUC0-t of Budesonide With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "AUC0-t of Formoterol With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "Cmax of Budesonide With and Without Charcoal Blockade", "description": "Maximum plasma level of budesonide with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "Cmax of Formoterol With and Without Charcoal Blockade", "description": "Maximum plasma level of formoterol with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}], "secondaryOutcomes": [{"measure": "AUC0-30 of Budesonide With and Without Charcoal Blockade.", "description": "Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-30 min (0, 2, 5, 10, 15, 20, and 30 min)"}, {"measure": "AUC0-30 of Formoterol With and Without Charcoal Blockade.", "description": "Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-30 min (0, 2, 5, 10, 15, 20, and 30 min)"}, {"measure": "AUC0-\u221e of Budesonide With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "AUC0-\u221e of Formoterol With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "Tmax for Budesonide With and Without Charcoal Blockade", "description": "Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "Tmax for Formoterol With and Without Charcoal Blockade", "description": "Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "t1/2 for Budesonide With and Without Charcoal Blockade", "description": "Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "t1/2 for Formoterol With and Without Charcoal Blockade", "description": "Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)"}, {"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 refers to the volume of air that an individual can exhale during a forced breath in 1 second.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.\n\nand Symbicort 2, together. Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together.\n\nBut some subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.", "timeFrame": "At 75 min (1.25 hours) post-dose"}, {"measure": "Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)", "description": "FVC = Forced vital capacity. It is the full amount of air that can be exhaled with effort in a complete breath.\n\nFEV1/FVC = Tiffenau-Pinelli Index. This parameter represents the measurement of the amount of air an individual can forcefully exhale from his/her lungs.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.\n\nPlease note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together.\n\nBut 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.", "timeFrame": "At 75 min (1.25 hours) post-dose"}, {"measure": "Change From Baseline in Peak Expiratory Flow Rate (PEFR)", "description": "PEFR is the highest rate at which gases can be expelled from the lungs via an open mouth. Its measurement is a simple procedure in which an individual takes a full inspiration and blows out as forcibly as possible into an instrument called a peak flow meter, which measures the maximal gas flow in an exhalation in liters per minute.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.", "timeFrame": "At 75 min (1.25 hours) post-dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Main Inclusion Criteria:\n\n* Male or female 18 to 45 years of age.\n* If female, is currently not pregnant/breast feeding/ or attempting to become pregnant has a negative serum pregnancy test, or is of non-childbearing potential or is of child-bearing potential, willing to commit to using a consistent and acceptable method of birth control or is of child-bearing potential and not sexually active\n* Body mass index (BMI) of 18.5 to 29.9 kg/m\u00b2 inclusive and a body weight \u226550 kg.\n\nMain Exclusion Criteria:\n\n* FEV1 value less than 80% of the predicted value and FEV1/FVC ratio \\<0.7.\n* History or current evidence of a clinically significant disease or disorder capable of altering the absorption, metabolism, distribution or elimination of drugs.\n* History or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, haematological, neuropsychological, endocrine, gastrointestinal or pulmonary.\n* Presence of glaucoma, cataracts, ocular herpes simplex, malignancy, regardless of the clinical significance or current stability of the disease.\n* History or presence of silent infections, including positive tests for HIV1, HIV2, Hepatitis B and Hepatitis C.\n* Bacterial or viral infection of the upper respiratory tract (including the common cold and flu), sinus, or middle ear within 2 weeks of dosing.\n* Lower respiratory tract infection/pneumonia within the past 3 months.\n* Presence of any disease or condition or regular concomitant treatment (including vitamins and herbal products) known to interfere with the absorption, distribution, metabolism or excretion of drugs.\n* Screening haemoglobin value of less than 1g/dL above the ULN (or 10g/L)\n* History of recurrent vasovagal collapses.\n* History of anaphylactic/anaphylactoid reactions.\n* History of seizures including febrile seizures excluding childhood febrile convulsions.\n* Unable to demonstrate proper inhalation techniques involved in using the delivery devices at screening.\n* Exposure to any investigational drug within 90 days of the Screening Visit.\n* Known or suspected hypersensitivity or idiosyncratic reaction to any steroid, any \u03b22 agonist,or to lactose monohydrate, leucine or Tween 80.\n* History of allergy to milk protein.\n* Use of an inhaled corticosteroid within 30 days or systemic corticosteroid within 60 days of the Screening Visit.\n* Use of medications or herbal medicines that are strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 30 days prior to Screening Visit\n* Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study.\n* Use of caffeine containing beverages more than 600 mg of caffeine/day.\n* Current smokers or ex-smokers who have stopped smoking for less than 10 years.\n* Recent or current (suspected) drug abuse or positive result in the drugs abuse test.\n* Recent or current alcohol abuse (regular drinking more than 21 units per week for males and more than 14 units per week for females \\[1 unit = 4 cl spirits or equivalent\\]).\n* Predictable poor compliance, intolerance to charcoal solution, or inability to communicate well with the study centre personnel or inability to participate in all treatment periods.\n* The subject is not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions, has participated in a clinical research study within the previous three months or has previously been enrolled in this study.", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Phil Evans, MBChB", "affiliation": "Quotient Clinical Limited", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Quotient Clinical Ltd", "city": "Ruddington", "zip": "NG11 6JS", "country": "United Kingdom", "geoPoint": {"lat": 52.89254, "lon": -1.14953}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects had to have an adequate inspiratory flow rate and be able to use both inhalers. Subjects who continued to meet all entry criteria on Day -1 of treatment Period 1 and with an inspiratory flow rate of \u226560 L/min and proper device use entered the treatment phase.", "recruitmentDetails": "Subjects were screened for eligibility -28 to -2 days prior to the first treatment period. On Day -1 of the first treatment period, i.d. before randomization, subjects were trained on both the RS01 and Symbicort Turbohaler devices.", "groups": [{"id": "FG000", "title": "A-B1-B2-C-D", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG001", "title": "B1-C-A-D-B2", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG002", "title": "C-D-B1-B2-A", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG003", "title": "D-B2-C-A-B1", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG004", "title": "B2-A-D-B1-C", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG005", "title": "D-C-B2-B1-A", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG006", "title": "B2-D-A-C-B1", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG007", "title": "A-B2-B1-D-C", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG008", "title": "B1-A-C-B2-D", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "FG009", "title": "C-B1-D-A-B2", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "9"}, {"groupId": "FG007", "numSubjects": "9"}, {"groupId": "FG008", "numSubjects": "9"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "A", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "8"}, {"groupId": "FG007", "numSubjects": "9"}, {"groupId": "FG008", "numSubjects": "9"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "B1", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "9"}, {"groupId": "FG007", "numSubjects": "9"}, {"groupId": "FG008", "numSubjects": "9"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "B2", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "9"}, {"groupId": "FG007", "numSubjects": "9"}, {"groupId": "FG008", "numSubjects": "8"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "C", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "9"}, {"groupId": "FG007", "numSubjects": "9"}, {"groupId": "FG008", "numSubjects": "9"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "D", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "9"}, {"groupId": "FG006", "numSubjects": "9"}, {"groupId": "FG007", "numSubjects": "9"}, {"groupId": "FG008", "numSubjects": "8"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "9"}, {"groupId": "FG005", "numSubjects": "8"}, {"groupId": "FG006", "numSubjects": "8"}, {"groupId": "FG007", "numSubjects": "9"}, {"groupId": "FG008", "numSubjects": "8"}, {"groupId": "FG009", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "1"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "1"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}, {"groupId": "FG008", "numSubjects": "0"}, {"groupId": "FG009", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety population: All subjects who received at least one dose (2 inhalations) of investigational medicinal product.", "groups": [{"id": "BG000", "title": "A-B1-B2-C-D", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG001", "title": "B1-C-A-D-B2", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG002", "title": "C-D-B1-B2-A", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG003", "title": "D-B2-C-A-B1", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG004", "title": "B2-A-D-B1-C", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG005", "title": "D-C-B2-B1-A", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG006", "title": "B2-D-A-C-B1", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG007", "title": "A-B2-B1-D-C", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG008", "title": "B1-A-C-B2-D", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG009", "title": "C-B1-D-A-B2", "description": "Subjects were dosed on Day 1 of each treatment period with one of the following 5 treatments according to the randomization schedule using a Williams Latin Square design:\n\n1. Treatment A: Z7200 without oral activated charcoal\n2. Treatment B1: Symbicort 1 without oral activated charcoal\n3. Treatment B1: Symbicort 2 without oral activated charcoal\n4. Treatment C: Z7200 with oral activated charcoal\n5. Treatment D: Symbicort with oral activated charcoal\n\nA washout period \u22655 days followed treatment periods 1 to 4.\n\nZ7200 without activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).\n\nSymbicort Turbohaler without activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).\n\nZ7200 with activated charcoal: 160 ug budesonide and 4.5 ug formoterol, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).\n\nSymbicort Turbohaler with activated charcoal: 320 ug budesonide and 9 ug formoterol, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation, with charcoal blockade (Treatment D)."}, {"id": "BG010", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "9"}, {"groupId": "BG005", "value": "9"}, {"groupId": "BG006", "value": "9"}, {"groupId": "BG007", "value": "9"}, {"groupId": "BG008", "value": "9"}, {"groupId": "BG009", "value": "9"}, {"groupId": "BG010", "value": "90"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "9"}, {"groupId": "BG005", "value": "9"}, {"groupId": "BG006", "value": "9"}, {"groupId": "BG007", "value": "9"}, {"groupId": "BG008", "value": "9"}, {"groupId": "BG009", "value": "9"}, {"groupId": "BG010", "value": "90"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.0", "spread": "7.9"}, {"groupId": "BG001", "value": "24.7", "spread": "6.5"}, {"groupId": "BG002", "value": "27.2", "spread": "6.0"}, {"groupId": "BG003", "value": "28.1", "spread": "7.4"}, {"groupId": "BG004", "value": "26.3", "spread": "7.6"}, {"groupId": "BG005", "value": "29.8", "spread": "8.5"}, {"groupId": "BG006", "value": "28.0", "spread": "7.6"}, {"groupId": "BG007", "value": "28.3", "spread": "5.9"}, {"groupId": "BG008", "value": "27.8", "spread": "8.9"}, {"groupId": "BG009", "value": "36.2", "spread": "5.0"}, {"groupId": "BG010", "value": "28.5", "spread": "7.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "5"}, {"groupId": "BG006", "value": "5"}, {"groupId": "BG007", "value": "3"}, {"groupId": "BG008", "value": "5"}, {"groupId": "BG009", "value": "4"}, {"groupId": "BG010", "value": "37"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "4"}, {"groupId": "BG006", "value": "4"}, {"groupId": "BG007", "value": "6"}, {"groupId": "BG008", "value": "4"}, {"groupId": "BG009", "value": "5"}, {"groupId": "BG010", "value": "53"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "3"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "1"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "1"}, {"groupId": "BG009", "value": "3"}, {"groupId": "BG010", "value": "5"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "8"}, {"groupId": "BG005", "value": "8"}, {"groupId": "BG006", "value": "7"}, {"groupId": "BG007", "value": "9"}, {"groupId": "BG008", "value": "8"}, {"groupId": "BG009", "value": "6"}, {"groupId": "BG010", "value": "80"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}, {"groupId": "BG009", "value": "0"}, {"groupId": "BG010", "value": "2"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "9"}, {"groupId": "BG005", "value": "9"}, {"groupId": "BG006", "value": "9"}, {"groupId": "BG007", "value": "9"}, {"groupId": "BG008", "value": "9"}, {"groupId": "BG009", "value": "9"}, {"groupId": "BG010", "value": "90"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "AUC0-t of Budesonide With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (160 ug budesonide)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (320 ug budesonide)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (160 ug budesonide)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (320 ug budesonide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1870", "spread": "20.2"}, {"groupId": "OG001", "value": "1360", "spread": "49.4"}, {"groupId": "OG002", "value": "1810", "spread": "22.3"}, {"groupId": "OG003", "value": "1330", "spread": "52.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "138.87", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "129.09", "ciUpperLimit": "149.39"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "136.18", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "126.13", "ciUpperLimit": "147.04"}]}, {"type": "PRIMARY", "title": "AUC0-t of Formoterol With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to the last detectable level calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (4.5 ug formoterol)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (9 ug formoterol)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (4.5 ug formoterol)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (9 ug formoterol)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.4", "spread": "26.0"}, {"groupId": "OG001", "value": "40.1", "spread": "58.6"}, {"groupId": "OG002", "value": "44.7", "spread": "26.8"}, {"groupId": "OG003", "value": "34.5", "spread": "78.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "119.73", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "109.40", "ciUpperLimit": "131.03"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "129.62", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "117.33", "ciUpperLimit": "143.20"}]}, {"type": "PRIMARY", "title": "Cmax of Budesonide With and Without Charcoal Blockade", "description": "Maximum plasma level of budesonide with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg/mL", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (160 ug budesonide)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (320 ug budesonide)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (160 ug budesonide)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (320 ug budesonide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1040", "spread": "67.7"}, {"groupId": "OG001", "value": "482", "spread": "63.4"}, {"groupId": "OG002", "value": "1090", "spread": "78.9"}, {"groupId": "OG003", "value": "542", "spread": "62.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "218.13", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "194.02", "ciUpperLimit": "245.24"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "200.66", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "174.30", "ciUpperLimit": "231.01"}]}, {"type": "PRIMARY", "title": "Cmax of Formoterol With and Without Charcoal Blockade", "description": "Maximum plasma level of formoterol with and without charcoal blockade. Participants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg/mL", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (4.5 ug formoterol)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (9 ug formoterol)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (4.5 ug formoterol)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (9 ug formoterol)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.9", "spread": "38.6"}, {"groupId": "OG001", "value": "9.53", "spread": "57.5"}, {"groupId": "OG002", "value": "12.4", "spread": "35.5"}, {"groupId": "OG003", "value": "10.6", "spread": "58.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "126.17", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "115.93", "ciUpperLimit": "137.32"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "Z7200 was considered bioequivalent to the reference if the following criteria were satisfied:\n\n* the 90%CI for the geometric mean AUC0-t ratio was within the interval 80.00% to 125.00% for both budesonide and formoterol, with and without charcoal blockade and\n* the 90%CI for the geometric mean ratio for Cmax was within the wider bioequivalence acceptance limits of (69.84%, 143.19%) for budesonide and (71.92%, 139.04%) for formoterol, respectively with and without charcoal blockade.", "pValue": "0.004", "statisticalMethod": "Mixed Models Analysis", "paramType": "Adjusted geometric means ratio", "paramValue": "117.08", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "107.05", "ciUpperLimit": "128.05"}]}, {"type": "SECONDARY", "title": "AUC0-30 of Budesonide With and Without Charcoal Blockade.", "description": "Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "0-30 min (0, 2, 5, 10, 15, 20, and 30 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (160 ug budesonide)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (320 ug budesonide)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (160 ug budesonide)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (320 ug budesonide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "324", "spread": "36.5"}, {"groupId": "OG001", "value": "174", "spread": "62.0"}, {"groupId": "OG002", "value": "342", "spread": "38.3"}, {"groupId": "OG003", "value": "193", "spread": "63.4"}]}]}]}, {"type": "SECONDARY", "title": "AUC0-30 of Formoterol With and Without Charcoal Blockade.", "description": "Area under the plasma concentration-time curve from time zero to 30 minutes calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "0-30 min (0, 2, 5, 10, 15, 20, and 30 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (4.5 ug formoterol)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (9 ug formoterol)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (4.5 ug formoterol)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (9 ug formoterol)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.85", "spread": "33.0"}, {"groupId": "OG001", "value": "3.12", "spread": "54.4"}, {"groupId": "OG002", "value": "4.00", "spread": "32.1"}, {"groupId": "OG003", "value": "3.35", "spread": "58.2"}]}]}]}, {"type": "SECONDARY", "title": "AUC0-\u221e of Budesonide With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (160 ug budesonide)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (320 ug budesonide)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (160 ug budesonide)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (320 ug budesonide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "163"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1980", "spread": "20.5"}, {"groupId": "OG001", "value": "1450", "spread": "48.8"}, {"groupId": "OG002", "value": "1900", "spread": "22.4"}, {"groupId": "OG003", "value": "1410", "spread": "50.1"}]}]}]}, {"type": "SECONDARY", "title": "AUC0-\u221e of Formoterol With and Without Charcoal Blockade", "description": "Area under the plasma concentration-time curve from time zero to infinity calculations were performed using the linear trapezoidal rule.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "pg*h/mL", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (4.5 ug formoterol)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (9 ug formoterol)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (4.5 ug formoterol)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (9 ug formoterol)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "75"}, {"groupId": "OG003", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "56.0", "spread": "28.2"}, {"groupId": "OG001", "value": "49.8", "spread": "57.1"}, {"groupId": "OG002", "value": "54.5", "spread": "27.7"}, {"groupId": "OG003", "value": "45.2", "spread": "61.6"}]}]}]}, {"type": "SECONDARY", "title": "Tmax for Budesonide With and Without Charcoal Blockade", "description": "Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (160 ug budesonide)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (320 ug budesonide)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (160 ug budesonide)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (320 ug budesonide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.75"}, {"groupId": "OG001", "value": "0.25", "lowerLimit": "0.03", "upperLimit": "1.50"}, {"groupId": "OG002", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.75"}, {"groupId": "OG003", "value": "0.25", "lowerLimit": "0.03", "upperLimit": "1.00"}]}]}]}, {"type": "SECONDARY", "title": "Tmax for Formoterol With and Without Charcoal Blockade", "description": "Time at which the maximum plasma level (Cmax) occurred with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (4.5 ug formoterol)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (9 ug formoterol)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (4.5 ug formoterol)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (9 ug formoterol)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "164"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "lowerLimit": "0.08", "upperLimit": "0.20"}, {"groupId": "OG001", "value": "0.08", "lowerLimit": "0.04", "upperLimit": "0.25"}, {"groupId": "OG002", "value": "0.08", "lowerLimit": "0.03", "upperLimit": "0.17"}, {"groupId": "OG003", "value": "0.08", "lowerLimit": "0.08", "upperLimit": "0.17"}]}]}]}, {"type": "SECONDARY", "title": "t1/2 for Budesonide With and Without Charcoal Blockade", "description": "Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "hours", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (160 ug budesonide)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (320 ug budesonide)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (160 ug budesonide)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (320 ug budesonide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "163"}, {"groupId": "OG002", "value": "84"}, {"groupId": "OG003", "value": "84"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.90", "spread": "17.0"}, {"groupId": "OG001", "value": "2.94", "spread": "19.8"}, {"groupId": "OG002", "value": "2.79", "spread": "17.0"}, {"groupId": "OG003", "value": "2.80", "spread": "15.8"}]}]}]}, {"type": "SECONDARY", "title": "t1/2 for Formoterol With and Without Charcoal Blockade", "description": "Apparent elimination half-life calculated as 0.693/lambda zeta, with and without charcoal blockade.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.", "populationDescription": "PK population included subjects who had received both test and reference for at least one dose of each treatment without or with oral charcoal.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "hours", "timeFrame": "0-24h (0, 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720, and 1440 min)", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal (160 ug budesonide)"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal (320 ug budesonide)"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal (160 ug budesonide)"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal (320 ug budesonide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "75"}, {"groupId": "OG003", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.57", "spread": "29.3"}, {"groupId": "OG001", "value": "9.33", "spread": "35.2"}, {"groupId": "OG002", "value": "10.09", "spread": "29.8"}, {"groupId": "OG003", "value": "9.15", "spread": "33.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 refers to the volume of air that an individual can exhale during a forced breath in 1 second.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.\n\nand Symbicort 2, together. Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together.\n\nBut some subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.", "populationDescription": "Safety population: all subjects who received at least one dose (2 inhalations) of investigational medicinal product", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "At 75 min (1.25 hours) post-dose", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "174"}, {"groupId": "OG002", "value": "87"}, {"groupId": "OG003", "value": "86"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "0.2"}, {"groupId": "OG001", "value": "0.2", "spread": "0.2"}, {"groupId": "OG002", "value": "0.2", "spread": "0.2"}, {"groupId": "OG003", "value": "0.2", "spread": "0.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Ratio of Forced Expiratory Volume in 1 Second to Forced Vital Capacity (FEV1/FVC)", "description": "FVC = Forced vital capacity. It is the full amount of air that can be exhaled with effort in a complete breath.\n\nFEV1/FVC = Tiffenau-Pinelli Index. This parameter represents the measurement of the amount of air an individual can forcefully exhale from his/her lungs.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.\n\nPlease note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together.\n\nBut 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.", "populationDescription": "Safety population: all subjects who received at least one dose (2 inhalations) of investigational medicinal product.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "At 75 min (1.25 hours) post-dose", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "174"}, {"groupId": "OG002", "value": "87"}, {"groupId": "OG003", "value": "86"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.7", "spread": "3.0"}, {"groupId": "OG001", "value": "3.6", "spread": "3.4"}, {"groupId": "OG002", "value": "3.2", "spread": "3.1"}, {"groupId": "OG003", "value": "3.8", "spread": "3.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Peak Expiratory Flow Rate (PEFR)", "description": "PEFR is the highest rate at which gases can be expelled from the lungs via an open mouth. Its measurement is a simple procedure in which an individual takes a full inspiration and blows out as forcibly as possible into an instrument called a peak flow meter, which measures the maximal gas flow in an exhalation in liters per minute.\n\nParticipants for the Treatment B are counted for both Symbicort 1 and Symbicort 2, together.Please note that, within the safety population, 90 subjects received Treatment B. This would mean that theorically 180 participants received Symbicort 1 and Symbicort 2, together. But 6 subjects were excluded from the statistical analysis for various reasons so that the total number included in the statistical anlysis for treatment B is 174.", "populationDescription": "Safety population: all subjects who received at least one dose (2 inhalations) of investigational medicinal product.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "At 75 min (1.25 hours) post-dose", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Z7200 without charcoal"}, {"id": "OG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal"}, {"id": "OG002", "title": "Treatment C", "description": "Z7200 with charcoal"}, {"id": "OG003", "title": "Treatment D", "description": "Symbicort with charcoal"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "174"}, {"groupId": "OG002", "value": "87"}, {"groupId": "OG003", "value": "86"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.2", "spread": "48.9"}, {"groupId": "OG001", "value": "20.5", "spread": "38.7"}, {"groupId": "OG002", "value": "24.8", "spread": "35.5"}, {"groupId": "OG003", "value": "19.2", "spread": "38.9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "Throughout the study till the end of trial assessment, which was completed on Day 2 of last treatment period (up to 6 weeks).", "eventGroups": [{"id": "EG000", "title": "Treatment A", "description": "Z7200 without charcoal", "deathsNumAffected": 0, "deathsNumAtRisk": 84, "seriousNumAffected": 0, "seriousNumAtRisk": 84, "otherNumAffected": 16, "otherNumAtRisk": 84}, {"id": "EG001", "title": "Treatment B", "description": "Symbicort 1+2 without charcoal", "deathsNumAffected": 0, "deathsNumAtRisk": 90, "seriousNumAffected": 0, "seriousNumAtRisk": 90, "otherNumAffected": 20, "otherNumAtRisk": 90}, {"id": "EG002", "title": "Treatment C", "description": "Z7200 with charcoal", "deathsNumAffected": 0, "deathsNumAtRisk": 88, "seriousNumAffected": 0, "seriousNumAtRisk": 88, "otherNumAffected": 6, "otherNumAtRisk": 88}, {"id": "EG003", "title": "Treatment D", "description": "Symbicort with charcoal", "deathsNumAffected": 0, "deathsNumAtRisk": 86, "seriousNumAffected": 0, "seriousNumAtRisk": 86, "otherNumAffected": 15, "otherNumAtRisk": 86}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 7, "numAffected": 7, "numAtRisk": 86}]}, {"term": "Migrane", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Oral Discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Oral Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Catheter site related reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Axillary pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Catheter site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Vessel puncture site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Dyspnoea exertional", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Eosinophil count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Blood pressure systolic increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Limb discomfort", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Muscular Weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Thooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Rash erythematous", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Acne", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 86}]}, {"term": "Blister", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Thermal Burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Eye Pain", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Euphoric mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (17.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 84}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 90}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 88}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 86}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Limitations and Caveats not specified"}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Isabella Salerio, PhD", "organization": "Zambon SpA", "email": "clinicaltrials@zambongroup.com", "phone": "+39 02665241"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}, {"id": "D000002606", "term": "Charcoal"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000931", "term": "Antidotes"}, {"id": "D000020011", "term": "Protective Agents"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M5852", "name": "Charcoal", "asFound": "Balance exercises", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4250", "name": "Antidotes", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}